USD 15.0
(1.35%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 48.18 Million USD | 106.82% |
2022 | 23.3 Million USD | 225.37% |
2021 | 7.16 Million USD | -78.25% |
2020 | 32.92 Million USD | 10.24% |
2019 | 29.86 Million USD | 11.7% |
2018 | 26.73 Million USD | 4518.13% |
2017 | 579 Thousand USD | -97.84% |
2016 | 26.83 Million USD | -0.35% |
2015 | 26.92 Million USD | 0.0% |
2014 | 26.92 Million USD | 0.0% |
2013 | - USD | -100.0% |
2012 | 26.92 Million USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | -100.0% |
2009 | 145.52 Thousand USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 59.23 Million USD | 15.45% |
2024 Q2 | 55.63 Million USD | 0.0% |
2023 Q3 | 51.04 Million USD | 27.16% |
2023 FY | 48.18 Million USD | 106.82% |
2023 Q1 | 40.14 Million USD | 72.3% |
2023 Q2 | 40.14 Million USD | 0.0% |
2023 Q4 | 51.04 Million USD | 0.0% |
2022 Q3 | 23.29 Million USD | 5474.16% |
2022 Q1 | 418 Thousand USD | -94.16% |
2022 Q4 | 23.3 Million USD | 0.0% |
2022 FY | 23.3 Million USD | 225.37% |
2022 Q2 | 418 Thousand USD | 0.0% |
2021 Q2 | 5.95 Million USD | -82.17% |
2021 FY | 7.16 Million USD | -78.25% |
2021 Q1 | 33.4 Million USD | 1.45% |
2021 Q4 | 7.16 Million USD | 0.0% |
2021 Q3 | 7.16 Million USD | 20.21% |
2020 Q4 | 32.92 Million USD | -1.73% |
2020 Q2 | 30.11 Million USD | 0.0% |
2020 Q1 | - USD | -100.0% |
2020 FY | 32.92 Million USD | 10.24% |
2020 Q3 | 33.5 Million USD | 11.25% |
2019 Q2 | 3.71 Million USD | -87.32% |
2019 Q4 | 30.44 Million USD | 646.41% |
2019 FY | 29.86 Million USD | 11.7% |
2019 Q1 | 29.28 Million USD | 9.52% |
2019 Q3 | 4.07 Million USD | 9.83% |
2018 FY | 26.73 Million USD | 4518.13% |
2018 Q1 | - USD | -100.0% |
2018 Q4 | 26.73 Million USD | 0.0% |
2018 Q2 | 26.69 Million USD | 0.0% |
2017 Q2 | 19.99 Million USD | -28.91% |
2017 Q3 | 579 Thousand USD | -97.1% |
2017 Q1 | 28.11 Million USD | 4.8% |
2017 FY | 579 Thousand USD | -97.84% |
2017 Q4 | 579 Thousand USD | 0.0% |
2016 Q4 | 26.83 Million USD | -23.25% |
2016 FY | 26.83 Million USD | -0.35% |
2016 Q3 | 34.95 Million USD | 30.45% |
2016 Q2 | 26.79 Million USD | -26.33% |
2016 Q1 | 36.37 Million USD | 35.12% |
2015 Q1 | 26.92 Million USD | 0.0% |
2015 Q3 | 26.92 Million USD | 0.0% |
2015 Q4 | 26.92 Million USD | 0.0% |
2015 FY | 26.92 Million USD | 0.0% |
2015 Q2 | 26.92 Million USD | 0.0% |
2014 Q1 | 26.92 Million USD | 0.0% |
2014 FY | 26.92 Million USD | 0.0% |
2014 Q2 | 26.92 Million USD | 0.0% |
2014 Q4 | 26.92 Million USD | 0.0% |
2013 Q1 | 26.92 Million USD | 0.0% |
2013 FY | - USD | -100.0% |
2013 Q3 | - USD | -100.0% |
2013 Q2 | 26.92 Million USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2012 Q3 | 39.39 Million USD | 46.31% |
2012 Q2 | 26.92 Million USD | 0.0% |
2012 FY | 26.92 Million USD | 0.0% |
2012 Q4 | 26.92 Million USD | -31.65% |
2011 FY | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 FY | - USD | -100.0% |
2009 FY | 145.52 Thousand USD | 0.0% |
2009 Q4 | 145.52 Thousand USD | 0.0% |
2008 FY | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2005 FY | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Esperion Therapeutics, Inc. | 501.54 Million USD | 90.392% |
Theratechnologies Inc. | 51.26 Million USD | 5.993% |
Safety Shot Inc | 304.9 Thousand USD | -15704.491% |
Cosmos Health Inc. | 3.03 Million USD | -1487.598% |
Cronos Group Inc. | 1.55 Million USD | -2991.02% |
Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 90.329% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | -40.945% |
Organogenesis Holdings Inc. | 60.74 Million USD | 20.67% |
Universe Pharmaceuticals INC | - USD | -Infinity% |
ProPhase Labs, Inc. | 10.25 Million USD | -369.77% |
Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -55289.655% |
Dynavax Technologies Corporation | 252.41 Million USD | 80.909% |
Radius Health, Inc. | 339.66 Million USD | 85.813% |
China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -41041.818% |
Alvotech | 1.02 Billion USD | 95.311% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | -8839.865% |
Alpha Teknova, Inc. | 13.25 Million USD | -263.663% |
Intra-Cellular Therapies, Inc. | 13.32 Million USD | -261.616% |
SCYNEXIS, Inc. | 12.15 Million USD | -296.324% |
Harrow Health, Inc. | 183.17 Million USD | 73.692% |
Biofrontera Inc. | 804 Thousand USD | -5893.657% |
DURECT Corporation | 2.7 Million USD | -1683.457% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -45.165% |
ANI Pharmaceuticals, Inc. | 309.66 Million USD | 84.439% |
OptiNose, Inc. | 611 Thousand USD | -7786.907% |
RedHill Biopharma Ltd. | 455 Thousand USD | -10490.989% |
Aquestive Therapeutics, Inc. | 91.07 Million USD | 47.089% |
Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -276.944% |
SIGA Technologies, Inc. | 335.99 Thousand USD | -14242.348% |
Lifecore Biomedical, Inc. | 120.51 Million USD | 60.012% |
Shineco, Inc. | 10.01 Million USD | -381.056% |
Phibro Animal Health Corporation | 458.28 Million USD | 89.485% |
Procaps Group S.A. | 28.41 Million USD | -69.62% |
TherapeuticsMD, Inc. | 6.53 Million USD | -637.737% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Viatris Inc. | 16.18 Billion USD | 99.702% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | -8839.865% |
Rockwell Medical, Inc. | 8.29 Million USD | -481.08% |
Incannex Healthcare Limited | 210 Thousand USD | -22847.143% |
Aytu BioPharma, Inc. | 10.87 Million USD | -343.036% |
Tilray Brands, Inc. | 287.93 Million USD | 83.264% |
Collegium Pharmaceutical, Inc. | 489.96 Million USD | 90.165% |
PetIQ, Inc. | 437.82 Million USD | 88.993% |
Silver Spike Investment Corp. | - USD | -Infinity% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | 81.344% |
Journey Medical Corporation | 14.62 Million USD | -229.565% |
Alimera Sciences, Inc. | 64.48 Million USD | 25.276% |
Petros Pharmaceuticals, Inc. | 6.85 Million USD | -602.734% |
Assertio Holdings, Inc. | 38.51 Million USD | -25.121% |
Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -35572.038% |
Embecta Corp. | 1.62 Billion USD | 97.035% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -214225.743% |
Procaps Group, S.A. | 28.41 Million USD | -69.62% |
PainReform Ltd. | 30 Thousand USD | -160530.0% |
Avadel Pharmaceuticals plc | 32.75 Million USD | -47.097% |
Hempacco Co., Inc. | 5.93 Million USD | -712.494% |
Talphera, Inc. | - USD | -Infinity% |
Pacira BioSciences, Inc. | 513.79 Million USD | 90.621% |
Alvotech | 1.02 Billion USD | 95.311% |
Lantheus Holdings, Inc. | 616.12 Million USD | 92.179% |
Kamada Ltd. | 7.43 Million USD | -547.876% |
Indivior PLC | 235.66 Million USD | 79.552% |
Currenc Group, Inc. | 2.5 Million USD | -1822.198% |
Evoke Pharma, Inc. | 5 Million USD | -863.78% |
Flora Growth Corp. | 942 Thousand USD | -5015.605% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -214225.743% |
Evolus, Inc. | 120.35 Million USD | 59.962% |
Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 91.821% |
Akanda Corp. | 2.49 Million USD | -1829.756% |